ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l-Glutamic Acid)-Combretastatin A4 Conjugate in Metastatic Breast Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature.Cancer immunology, immunotherapy : CII · 2024Pooled it
- Novel therapeutic strategies for non-small cell lung cancer: Combination therapies with immune checkpoint inhibitors (Review).Oncology letters · 2025Review
- Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment.Journal of translational medicine · 2025Review
- Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.Discover oncology · 2025Review
- Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention.Heliyon · 2024Review
- The Effects of Hypoxia on the Immune-Metabolic Interplay in Liver Cancer.Biomolecules · 2024Article
- An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.Clinical and experimental medicine · 2024Review
- Review
- Research progress on the role of tumor‑associated macrophages in tumor development and their use as molecular targets (Review).International journal of oncology · 2024Review
- Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy.Nature communications · 2024Article
- Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities.Biomarker research · 2024Review
- Therapeutic effects and underlying mechanism of poly (L-glutamic acid)-Frontiers in bioengineering and biotechnology · 2024Article
- Combretastatin A-4 suppresses the invasive and metastatic behavior of glioma cells and induces apoptosis in them: in-vitro study.Medical oncology (Northwood, London, England) · 2023Article
- Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage.Journal of nanobiotechnology · 2023Article
- Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.Cancer medicine · 2023Review
- Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The emerging roles of metabolism in the crosstalk between breast cancer cells and tumor-associated macrophages.International journal of biological sciences · 2023Review
- Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy.Frontiers in immunology · 2023Review
- Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy.Frontiers in immunology · 2023Review
- Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)-International journal of nanomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular disrupting agents (VDAs) have great potential for cancer treatment. Poly(l-glutamic acid)-combretastatin A4 conjugate (PLG-CA4) is a novel class of VDAs. Though it has notable antitumor activity, it can induce host immune responses that promote tumor growth. Here, PLG-CA4 induces the polarization of tumor-associated macrophages (TAMs) toward the M2-like phenotype in 4T1 metastatic breast cancer (Control 30% vs PLG-CA4 53%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.